Member Info for mulledwine

It all depends on how ZOO adapt to the changing entertainment business - ebooks etc will be their salvation - hopefully buys from directors and staff back that up through internal confidence.

Purchase of shares by Chairman and employee trust ZOO announces that it was notified yesterday that, on the same day, Roger Jeynes (non executive Chairman of the Company) and the ZOO Employee Share Trust Limited ("ZEST") purchased, in aggregate, 250,000 ordinary shares of 15 pence each in the capital of the Company ("Ordinary Shares"). Roger Jeynes purchased 100,000 Ordinary Shares at 9.5 pence per Ordinary Shares, after which he is interested in 120,000 Ordinary Shares, representing 0.04% of the Company's issued share capital. ZEST purchased 150,000 Ordinary Shares at an average price of 9.2 pence per Ordinary Share (with individual trades ranging between 9.0 and 9.5 pence per Ordinary Share), after which ZEST is interested in 534,105 Ordinary Shares, representing 1.63% of the Company's issued share capital. ZEST is the beneficial owner of 292,539 of these Ordinary Shares, the balance being held in trust by ZEST on behalf of employees

http://www.investegate.co.uk/Article.aspx?id=201201060700110997V

Jeremy Ben-David, Waterlogic, Group CEO, commented: "We are very excited to announce the acquisition of DSK, our first since our IPO, which represents excellent value. DSK is a profitable and highly complementary business, allowing the introduction of Waterlogic's point-of-use water purification technology and associated products into the DSK customer base. The DSK coffee machine business will also be expanded into the existing Waterlogic customer base and branch offices throughout Norway and Denmark. We are making good progress with our attractive pipeline of future acquisition opportunities and we look forward to updating shareholders in due course." Erik Gulbrandsen, MD of Waterlogic Norway and Denmark, commented: "The acquisition of DSK is an obvious opportunity to further strengthen Waterlogic's leading position in Norway and Denmark. This will help to ensure our combined client base has full access to products from both DSK and Waterlogic, in addition to the expected costs savings and other synergies from the combined group. We have known the DSK team for a long time and look forward to working more closely with them going forward."

Acquisition of DSK Waterlogic Plc (AIM: WTL.L), a leading manufacturer and global distributor of point-of-use ("POU") drinking water purification and dispensing systems, is pleased to announce that it has agreed to acquire from Hart AS, Ludwig Hart and the Estate of Johs Lunde Group the entire issued share capital of Det Stavangerske Kaffeselskap ("DSK"), a leading vendor of water dispensers and coffee machines based in Norway, for a total cash consideration of USD 1.46 million, subject to, inter alia, approval of the Norwegian Competition Authority. DSK has an existing contracted customer base of water dispenser and coffee machine users located near Waterlogic's Stavanger offices. Following completion, DSK will be merged into Waterlogic Norway during 2012, with the aim of driving turnover and profit growth from cross-selling opportunities and achieving synergies and cost savings in the combined entity. The audited financial statements of DSK for the full year ending 31 December 2010 show revenues of USD 3.84 million and EBITDA of USD 0.50 million (after adding back non recurring payments made to shareholders).

http://www.investegate.co.uk/Article.aspx?id=201201060700101007V

Commenting, Jordan Soko, Acting Chief Executive of African Copper Plc, said, "The additional funds raised will provide the Company with the working capital to continue to improve production levels and highlights the continuing support of ZCI."

African Copper Plc: USD2.0 Million Working Capital Facility LONDON, UNITED KINGDOM--(Marketwire - Jan. 6, 2012) - African Copper (AIM:ACU)(BOTSWANA:AFRICAN COPPER), the copper production and exploration company, focussed on Botswana, announces that it has secured an additional loan of USD2.0 million from its controlling shareholder ZCI Limited ("ZCI"). The purpose of the new loan is to provide the Company with further working capital for its Mowana Mine facilities. The new USD2.0 million loan from ZCI is a secured loan facility with an interest rate of 9.0 per cent., repayable on 31 March 2013 (the "Facility"). Interest will be accrued annually and interest payments deferred until 31 March 2013. The terms and conditions of the Facility are on substantially similar terms to the previous term loans from ZCI and bring ACU's total interest-bearing loans (including accrued interest) from ZCI to USD64.9 million, excluding the existing convertible loan of a further USD8.4 million. As ZCI owns 84.19 per cent. of ACU's total issued ordinary share capital at the date of this announcement and is providing financing to the Company, the Facility falls within the definition of a related party transaction under Rule 13 of the AIM Rules for Companies. The independent directors of the Company consider, having consulted with its nominated adviser Canaccord Genuity Limited, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.

http://www.investegate.co.uk/Article.aspx?id=20120106070025M6493

Delays are hopefully just that with the end result being the same

Thomas A. Nicolette, Chief Executive of ABI, commented, "Although we were profoundly disappointed in the severe delay related to our supply agreement with Pulse, the increase in PIFA sales, the market acceptance of the BreathScan alcohol awareness programmes, and our pending product launches keep us focused on success during 2012."

Trading Update Akers Biosciences, Inc. (AIM:AKR), is an innovative designer and manufacturer of rapid diagnostic screening and testing products. The Company announces that chiefly due to issues with an order from Pulse Health, revenues for 2011 will be significantly below expectation with turnover expected to be approximately US $2.2M and that consequently proforma losses will be in the region of US $1.9M, though these figures may be subject to change. In June 2011, it was announced that ABI had secured a purchase order totaling US$3,242,200 to manufacture and supply Revelar Breath Tubes to Pulse Health, LLC under the Company's supply agreement. This was the first purchase order under the supply agreement and manufacturing commenced immediately at ABI's New Jersey facility. It was anticipated that the majority of this order would be fulfilled during 2011. In the latter part of 2011, Pulse experienced difficulties in the manufacture of their reagent which was to be supplied to ABI. This resulted in severe delays in the Company's production schedule. ABI continues to manufacture the Tubes currently, but the quantities delivered to Pulse are lower than originally planned due to Pulse's reagent formulation problems. As a result of these events that were out of the Company's control, it is with regret that ABI informs the market that turnover in relation to the Revelar Breath Tubes during 2011 will be approximately US$1.2M lower than expected. In addition, sales of BreathScan, the Company's line of disposable breath alcohol detectors have slowed over the prior year, partially due to the US government's failure to achieve the passing of its budget. This has lead to a strategic shift in the way ABI will structure its breath alcohol business segment. Moving forward, the products will be integrated into comprehensive alcohol awareness programmes focused on government and corporate sectors. To view the new initiative, please visit www.breathscan.com With regard to the Company's core product, sales of the PIFA Heparin/PF4 Rapid Assay continued to show improvement during 2011 with revenues approximately 23 per cent higher than in 2010. (PIFA sales 2011, H1 $583,473; H2 $643,192). The PIFA HPF4 test is the only FDA-cleared device that quickly determines if a patient, being treated with the blood thinner Heparin, may be developing a drug allergy that can result in life- and limb-threatening blood clots. Q1 2012 will mark the launch of the PIFA PLUSS PF4 rapid assay, a product line extension of ABI's growing heparin-allergy platform.

http://www.investegate.co.uk/Article.aspx?id=201201060700111027V

Pre Close Statement Tullett Prebon plc (the "Company") is today issuing a trading update ahead of the close period for the year ended 31 December 2011. The Company expects to announce its preliminary results for the year ended 31 December 2011 on 6 March 2012. Business Update The world's financial markets have remained unsettled throughout the year. There have been periods of market volatility and heightened activity, although there have also been periods of more subdued activity. Revenue for the year ended 31 December 2011 is expected to be in line with the £908.5m reported for 2010. Using constant exchange rates, and adjusting for the impact of the closure in 2010 of the satellite offices in North America and for the recent acquisition of Convenç�£o, revenue is expected to be around 2% higher. The acquisition of Chapdelaine & Co., which was announced on 18 November 2011, has completed, with an effective date of 1 January 2012. In the light of the market conditions a number of actions were taken prior to the year end to reduce costs and to maintain flexibility in the cost base. A charge reflecting these actions of around £10m will be included in the 2011 accounts. Further actions will be taken in the first half of 2012.

http://www.investegate.co.uk/Article.aspx?id=20120105070000P583C

Eurasian Natural Resources Corporation (ENRC) has agreed to buy the residual assets of the Kolwezi Tailings project and Frontier and Lonshi mines in the Democratic Republic of Congo for 1.25 billion dollars (0.80 billion pounds). The mining group will now look to buy the underlying licences at the mines to allow development of the projects. The consideration consists of an initial payment of 750 million dollars (481.8 million pounds) and a three year deferred 3% coupon of 500 million dollars (321.2 million pounds). Eurasian shares jumped 30.5p to 695p.

Shore Capital maintained its "buy" recommendation for Experian (EXPN) ahead of its third quarter trading update due on 17th January. The credit checker should deliver continued growth, ranging from the high teens in Brazil to single figure in North America, says the broker. Additionally, Shore believes the acquisition of Latin American credit services company Computec will give growth a further boost from the third quarter and into 2013. The shares fell 12.5p to 854p.

Daniel Stewart initiated coverage of DDD Group (DDD) with a "buy" recommendation and 50p target price. The broker expects the rate of conversion to 3D formats to accelerate, driven by digital cinema and next generation gaming, and believes the market will be worth 22 billion dollars (14.2 billion pounds) by 2018. With an established network of licensing agreement in TV, PC and mobile devices, having signed contracts with Sony and Lenovo, Daniel Stewart believes the 3D technology developer is well positioned to benefit from the increased demand. DDD shares inched up 0.125p to 26.625p.

Marjorie Scardino, Chief Executive of Financial Times publisher Pearson, has marked her fifteenth anniversary in the role with the purchase of 374 American Depository Receipts (ADRs). ADRs represent the ownership of shares in a non-US company. The purchase was made as part the firm's employee stock purchase plan, which gives employees the opportunity to purchase ordinary shares in Pearson at a discount. According to the stock exchange statement, Scardino paid $16.04 per share.

lex Kanellis, Chief Executive of PZ Cussons Plc, said: "The acquisition of Fudge further strengthens our newly formed beauty division and broadens its category participation. The geographic and distribution footprint of Fudge is a perfect fit with the current brand portfolio and we see further opportunity to develop the brand's international potential. Following this acquisition our balance sheet remains strong giving us flexibility for further investment opportunities as they arise." Michelle Feeney, Chief Executive of PZ Cussons Beauty, said: "We are delighted to be acquiring such a young, vibrant brand and I am very excited about its prospects and untapped potential. Fudge is a natural fit for our portfolio as we continue to bring well-loved brands back to the forefront and make beauty accessible to all."